PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)

• Masoom Priyadarshini,
• Zaneta Balantac,
• Simran K Tiwana,
• Shweta S Bapat,
• Sean Garrison,
• Mona L Martin

Affiliations

Masoom Priyadarshini

1 Bristol Myers Squibb, Princeton, United States

Zaneta Balantac

2 Evidera, Bethesda, United States

Simran K Tiwana

1 Bristol Myers Squibb, Princeton, United States

Shweta S Bapat

2 Evidera, Bethesda, United States

Sean Garrison

1 Bristol Myers Squibb, Princeton, United States

Mona L Martin

2 Evidera, Bethesda, United States